Is Xenon Pharmaceuticals Stock a Good Investment?
Xenon Pharmaceuticals Investment Advice | XENE |
- Examine Xenon Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Xenon Pharmaceuticals' leadership team and their track record. Good management can help Xenon Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceutical Products space and any emerging trends that could impact Xenon Pharmaceuticals' business and its evolving consumer preferences.
- Compare Xenon Pharmaceuticals' performance and market position to its competitors. Analyze how Xenon Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Xenon Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Xenon Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Xenon Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Xenon Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Xenon Pharmaceuticals Stock
Researching Xenon Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 100.0% of the company outstanding shares are owned by institutional investors. The book value of Xenon Pharmaceuticals was at this time reported as 12.31. The company recorded a loss per share of 2.81. Xenon Pharmaceuticals had not issued any dividends in recent years.
To determine if Xenon Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Xenon Pharmaceuticals' research are outlined below:
| Xenon Pharmaceuticals generated a negative expected return over the last 90 days | |
| Net Loss for the year was (182.39 M) with loss before overhead, payroll, taxes, and interest of (177.91 M). | |
| Xenon Pharmaceuticals currently holds about 788.24 M in cash with (145.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.66. | |
| Over 100.0% of the company outstanding shares are owned by institutional investors |
Xenon Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Xenon Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Xenon Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Xenon Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.09 B.Basic technical analysis of Xenon Stock
As of the 31st of January, Xenon Pharmaceuticals maintains the Mean Deviation of 1.76, standard deviation of 2.31, and Market Risk Adjusted Performance of (0.02). Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Xenon Pharmaceuticals, as well as the relationship between them. Please check out Xenon Pharmaceuticals market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Xenon Pharmaceuticals is priced fairly, providing market reflects its latest price of 40.47 per share. Given that Xenon Pharmaceuticals has information ratio of (0.05), we strongly advise you to confirm Xenon Pharmaceuticals's prevalent market performance to make sure the company can sustain itself at a future point.Xenon Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Xenon Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Xenon Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Xenon Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Xenon Pharmaceuticals' Outstanding Corporate Bonds
Xenon Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Xenon Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Xenon bonds can be classified according to their maturity, which is the date when Xenon Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Understand Xenon Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Xenon Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.02) | |||
| Mean Deviation | 1.76 | |||
| Coefficient Of Variation | (9,716) | |||
| Standard Deviation | 2.31 | |||
| Variance | 5.33 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.28) | |||
| Treynor Ratio | (0.03) | |||
| Maximum Drawdown | 12.08 | |||
| Value At Risk | (3.82) | |||
| Potential Upside | 3.39 | |||
| Skewness | (0.82) | |||
| Kurtosis | 1.56 |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.02) | |||
| Mean Deviation | 1.76 | |||
| Coefficient Of Variation | (9,716) | |||
| Standard Deviation | 2.31 | |||
| Variance | 5.33 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.28) | |||
| Treynor Ratio | (0.03) | |||
| Maximum Drawdown | 12.08 | |||
| Value At Risk | (3.82) | |||
| Potential Upside | 3.39 | |||
| Skewness | (0.82) | |||
| Kurtosis | 1.56 |
Consider Xenon Pharmaceuticals' intraday indicators
Xenon Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Xenon Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Xenon Pharmaceuticals time-series forecasting models is one of many Xenon Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Xenon Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Xenon Stock media impact
Far too much social signal, news, headlines, and media speculation about Xenon Pharmaceuticals that are available to investors today. That information is available publicly through Xenon media outlets and privately through word of mouth or via Xenon internal channels. However, regardless of the origin, that massive amount of Xenon data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Xenon Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Xenon Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Xenon Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Xenon Pharmaceuticals alpha.
Xenon Pharmaceuticals Corporate Management
| Robin Sherrington | Sr. VP of Bus. and Corporate Devel. | Profile | |
| CMA CPA | CEO Pres | Profile | |
| MBA MPH | Chief Officer | Profile | |
| Sherry Aulin | Chief Officer | Profile | |
| Christopher MD | Chief Officer | Profile | |
| Andrea JD | Chief Secretary | Profile | |
| MBA MSc | Ex Operations | Profile |
Already Invested in Xenon Pharmaceuticals?
The danger of trading Xenon Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Xenon Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Xenon Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Xenon Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenon Pharmaceuticals. If investors know Xenon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Xenon Pharmaceuticals is measured differently than its book value, which is the value of Xenon that is recorded on the company's balance sheet. Investors also form their own opinion of Xenon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xenon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xenon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Xenon Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.